Screener
Exelixis EXEL Accrued clinical trial liabilities
Accrued clinical trial liabilities at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept exel:AccruedClinicalLiabilitiesCurrent.
The source filing: Exelixis’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q3 2026
- Accession
- 0000939767-26-000098
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $39,062 | $29,623 |
| Accrued compensation and benefits | 68,629 | 102,218 |
| Accrued clinical trial liabilities | 59,767 | 65,742 |
| Rebates and fees due to customers | 66,711 | 59,896 |
| Accrued collaboration liabilities | 25,096 | 22,783 |
| Other current liabilities | 102,662 | 125,382 |
| Total current liabilities | 361,927 | 405,644 |
Item 1. Financial Statements.
FAQ
- What is Exelixis's accrued clinical trial liabilities?
- Exelixis (EXEL) reported accrued clinical trial liabilities of $59.77M in Q2 2026.
- How has Exelixis's accrued clinical trial liabilities changed year-over-year?
- Exelixis's accrued clinical trial liabilities increased by 3.3% year-over-year, from $57.87M to $59.77M.
- What is the long-term trend for Exelixis's accrued clinical trial liabilities?
- Over 5 years (2020 to 2025), Exelixis's accrued clinical trial liabilities has grown at a 4.7% compound annual growth rate (CAGR), from $52.25M to $65.74M.
- What does accrued clinical trial liabilities mean?
- This represents the estimated costs incurred for ongoing clinical trials that have not yet been invoiced or paid to contract research organizations (CROs) or clinical sites. It is a critical metric for biopharmaceutical companies to track the true burn rate of their R&D pipeline.
Ask your AI about Exelixis's accrued clinical trial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude